Computerized Cognitive Tests for Neurological Disease

Overseen By Alexander Cervinsky, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: NYU Langone Health

Disqualifiers: Severe dementia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests new computerized tools designed to assess brain function. Researchers aim to determine if these digital tests match or surpass traditional paper-and-pencil tests. The study involves two groups: one with neurological issues identified through brain scans and one without. Participants should not have severe dementia and must be able to complete the tests. This trial may suit individuals with or without neurological findings who can perform basic computer tasks. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance future brain assessments.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that these computerized cognitive tests are safe for participants?

Research has shown that computerized brain tests are generally safe for use. Studies have found that these tests provide consistent results over time, indicating they do not harm or stress participants. These tests are widely used to identify issues like mild memory loss and dementia, demonstrating their safety and utility. No major negative effects have been reported in these studies, supporting the conclusion that participants handle these tests well. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the computerized cognitive tests for neurological diseases because they offer a new, tech-driven approach to diagnosing and understanding these conditions. Unlike standard treatments that focus on medication or physical therapy, this tool uses digital neuropsychological assessments to provide more detailed insights into cognitive function. By utilizing a computerized format, it allows for more precise and consistent monitoring over time, potentially leading to earlier detection and more personalized treatment plans. This innovative approach could revolutionize how cognitive impairments are assessed and managed, offering a non-invasive and easily accessible option for patients.

What evidence suggests that this computerized tool is effective for testing cognitive functioning?

Research shows that computerized tools hold promise for assessing brain function. Studies have found these digital tools to be as reliable and accurate as traditional paper-and-pencil tests. For instance, new computerized tests effectively evaluate conditions like mild cognitive impairment (MCI) and dementia. Some studies have found that incorporating artificial intelligence (AI) in these tools enhances the accuracy of diagnosing cognitive problems. Overall, these digital tests demonstrate potential in providing accurate and efficient brain function assessments. Participants in this trial will undergo evaluation using a Computer-based Neuropsychological Tool to assess its effectiveness across different groups, including those with cerebral neurological illness (CNI) and those without. ^{3 6 7 8 9}

Who Is on the Research Team?

Alexander Chervinsky, PhD

Principal Investigator

NYU Langone Health

Are You a Good Fit for This Trial?

This trial is for men and women aged 21-65, both healthy individuals and those with significant brain findings on neuroimaging. Participants must have good perception and motor skills to do the tests but can't join if they have severe dementia or lack the necessary perceptual/motor abilities.

Inclusion Criteria

I am between 21 and 65 years old.

Individuals without positive cerebral findings on neuroimaging (Non-PCF)

I am between 21 and 65 years old.

Exclusion Criteria

I am physically and mentally able to participate in tests.

I do not have severe dementia that affects my understanding.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Testing

Participants complete both computerized and paper-and-pencil neuropsychological tests to assess reliability and validity

4-6 weeks

1 visit (in-person)

Follow-up

Participants are monitored for any changes in cognitive performance post-testing

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Computer-based Neuropsychological Tool

Trial Overview The study is testing three new computer-based cognitive function tests against traditional paper-and-pencil methods. It aims to see if these digital tasks are more effective by comparing results from healthy controls and patients with neurological impairments.

How Is the Trial Designed?

Group I: Non-CNI participants Active Control 10 Interventions

Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message

Group II: Cerebral neurological illness (CNI) participants Active Control 10 Interventions

Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials

1,431

Recruited

838,000+

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12059415/

Moving toward the digitalization of neuropsychological tests This study evaluates the usability of digital neuropsychological assessment tools and examines healthcare professionals' perceptions of their reliability and ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10820741/

Applications of Artificial Intelligence in the Neuropsychological ... One study proposed a computer-aided diagnosis (CAD) system using AI to analyze CDT and provide an automatic diagnosis of cognitive impairment ( ...

3. karger.com karger.com/dem/article/54/2/109/913853/Current-Advances-in-Computerized-Cognitive

Current Advances in Computerized Cognitive Assessment ... The review highlights the advancements in computerized cognitive assessments for assessing MCI and dementia.

4. nature.com nature.com/articles/s41598-025-85614-x

Predictive value of an unsupervised web-based ... The current study examined whether functional deficits in the mnestic and attentive domain can be predicted based on an unsupervised self-administered online ...

5. sciencedirect.com sciencedirect.com/science/article/pii/S1532046422001241

Ensemble of models with feature space heterogeneity and ... This study aimed to develop and validate computerized neuropsychological assessment devices for screening patients with mild cognitive impairment (MCI).

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC3847815/

Computerized Neuropsychological Assessment Devices This paper is intended to provide guidance for test developers and users of CNADs that will promote accurate and appropriate use of computerized tests.

7. sciencedirect.com sciencedirect.com/science/article/pii/S227458072400517X

Current State of Self-Administered Brief Computerized ... We conducted a systematic review of self-administered computerized cognitive assessment measures designed for the detection of cognitive impairment in older ...

8. nature.com nature.com/articles/s41746-025-01583-5

A scoping review of remote and unsupervised digital ... Remote and unsupervised digital assessments can improve scalability, measurement reliability, and ecological validity, enabling the capture of subtle changes.

9. alz-journals.onlinelibrary.wiley.com alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/dad2.12083

cCOG: A web‐based cognitive test tool for detecting ... We examined accuracy and consistency of cCOG, a computerized cognitive tool, in detecting mild cognitive impairment (MCI) and dementia. Methods.